Chlornaphazine

CHEMBL2107519 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
268.2 g/mol
LogP
4.5
Phase
4

An obsolete alkylating agent and nitrogen mustard derivative that was used historically for the treatment of polycythemia vera and Hodgkin's disease. It was withdrawn from use due to a high incidence of bladder cancer associated with its metabolic conversion to aromatic amine carcinogens. It is an important example of a drug withdrawn due to its carcinogenic potential.

Moleküler Ağırlık

268,2000 g/mol

LogP

4,50

TPSA

3,20 Ų

Lipinski RO5

Geçer

Etki Mekanizması

Forms covalent bonds with DNA bases, creating cross-links and strand breaks that prevent DNA replication and transcription. This triggers apoptosis in rapidly dividing cells, particularly cancer cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Forms covalent bonds with DNA bases, creating cross-links and strand breaks that prevent DNA replication and transcription. This triggers apoptosis in rapidly dividing cells, particularly cancer cells.

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

ClCCN(CCCl)c1ccc2ccccc2c1

InChI

InChI=1S/C14H15Cl2N/c15-7-9-17(10-8-16)14-6-5-12-3-1-2-4-13(12)11-14/h1-6,11H,7-10H2

Molecular Formula

C14H15Cl2N

HBD / HBA

- / 1

Döndürülebilir Bağlar

5

Ağır Atomlar

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

An obsolete alkylating agent and nitrogen mustard derivative that was used historically for the treatment of polycythemia vera and Hodgkin's disease. It was withdrawn from use due to a high incidence of bladder cancer associated with its metabolic conversion to aromatic amine carcinogens. It is an important example of a drug withdrawn due to its carcinogenic potential.

Forms covalent bonds with DNA bases, creating cross-links and strand breaks that prevent DNA replication and transcription. This triggers apoptosis in rapidly dividing cells, particularly cancer cells.

Yes, Chlornaphazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2107519. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 10307. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.